PathMaker Neurosystems is developing non-invasive neuromodulation systems for ALS, spasticity, and other chronic neuromotor disorders. Its work is centered on abnormal motor excitability, including conditions where impaired neural control contributes to muscle weakness, stiffness, or loss of movement function.

Its MyoRegulator platform uses proprietary multi-site direct current stimulation across spinal and peripheral pathways. The goal is to modulate neural circuits involved in motor control through an external stimulation system, with programs spanning ALS and post-stroke upper-limb spasticity.

PathMaker remains in clinical development, with FDA Breakthrough Device Designation for ALS and earlier clinical work in spasticity. Its placement on the map is as a clinical-stage neurotherapeutics company focused on non-invasive stimulation for serious motor disorders.